Publications (17) Ana Maria Hurtado Lopez publications

2023

  1. Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial

    Frontiers in Oncology, Vol. 13

  2. NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition

    British Journal of Haematology, Vol. 201, Núm. 3, pp. 470-479

2022

  1. Antitumoral Effects of Tricyclic Antidepressants: Beyond Neuropathic Pain Treatment

    Cancers, Vol. 14, Núm. 13

2020

  1. Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach

    OncoImmunology, Vol. 9, Núm. 1

  2. Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia

    Haematologica, Vol. 105, Núm. 1, pp. 112-123

  3. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease

    Nature Communications, Vol. 11, Núm. 1

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

  2. Increasing therapy-related myeloid neoplasms in multiple myeloma

    European Journal of Clinical Investigation, Vol. 49, Núm. 2

2018

  1. An early increase of CD56 bright natural killer subset as dominant effect and predictor of response to extracorporeal photopheresis for graft-versus-host disease

    Transfusion, Vol. 58, Núm. 12, pp. 2924-2932

  2. An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups

    International Journal of Laboratory Hematology, Vol. 40, Núm. 5, pp. 549-555

  3. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes

    Haematologica

  4. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia

    British Journal of Haematology, Vol. 182, Núm. 3, pp. 373-383

2017

  1. Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger

    Pharmacogenetics and Genomics, Vol. 27, Núm. 2, pp. 70-77

2016

  1. A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients

    American Journal of Hematology

  2. Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: Kinetics, clinical impact and absence of STAT3 mutations

    British Journal of Haematology, Vol. 172, Núm. 6, pp. 937-946

2015

  1. Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia

    Blood Cancer Journal, Vol. 5

2012

  1. Taller de insulinización para enfermería y su aplicación en la práctica clínica

    XVI Encuentro Internacional de Investigación en Cuidados